Drug intelligence / Profile preview

PAS-010

Development stage: Preclinical
Lead developer: Porton Advanced Solutions
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

PAS-010 is a chimeric antigen receptor (CAR) T-cell therapy developed by Porton Advanced for the treatment of advanced ovarian carcinoma. The therapy utilizes T cells engineered to express a CAR specific for mesothelin, a cell-surface glycoprotein frequently overexpressed in ovarian cancers. By targeting mesothelin, PAS-010 facilitates the recognition and subsequent destruction of tumor cells through T-cell mediated cytotoxicity. The program is currently in the IND-enabling stage and has received Investigational New Drug (IND) approval from the NMPA in China.

Beyond the preview

Go deeper on PAS-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAS-010.

Explore the full profile